Reproductive Medicine Associates of Florida (RMA-FL) to Offer Advanced Lab Techniques and Proven IVF Treatment Plans to Hopeful Parents
BASKING RIDGE, N.J. (Dec. 11, 2017) – Starting today, IVI-RMA Global, the largest group dedicated to assisted reproduction in the world, welcomes patients to its newest U.S. office, Reproductive Medicine Associates of Florida (RMA-FL). Located at 400 Colonial Center Parkway in Lake Mary, the practice specializes in providing well-validated and effective fertility solutions for hopeful parents trying to have a baby.
RMA-FL patients will benefit from the cutting-edge infertility treatment and research conducted by IVI-RMA’s worldwide network of fertility clinics, including its U.S. flagship practice, Reproductive Medicine Associates of New Jersey (RMANJ).
RMANJ is one of the largest and most successful in vitro fertilization (IVF) programs in the U.S., with delivery rates about 20 percent higher than national average*, according to annual data released recently by the Society for Assisted Reproductive Technology (SART) for the year ending December 2014.
George Patounakis, M.D., Ph.D., F.A.C.O.G, serves as Medical Director and Lead Physician for RMA-FL. He is also an Assistant Professor of Obstetrics and Gynecology with the University of Central Florida, College of Medicine.
A research scientist and a former fellow of the National Institutes of Health in Bethesda, Maryland, Dr. Patounakis complements the IVI-RMA Global community’s strong focus on research, which has served to advance the field of reproductive endocrinology in the United States and around the world. Dr. Patounakis earned his Ph.D. in electrical engineering from Columbia University before pursuing a medical degree from Robert Wood Johnson Medical School at Rutgers University.
“As a reproductive endocrinologist, I understand it’s not just about getting pregnant – the true measure of success is delivery rates,” said Dr. Patounakis. “With a focus on single embryo transfer (SET), our practice leverages treatment paradigms that have healthier outcomes for mothers and babies by removing the risks and costs associated with multiple births.”
“Patients have traveled from more than 40 countries and 30 states, including Florida, to our New Jersey-based practice, so we knew that expanding our internationally-recognized, award-winning evidence-based fertility treatment protocols to Central Florida would be well-received,” said IVI-RMA Global CEO, Richard T. Scott, Jr., M.D., F.A.C.O.G., H.C.L.D./A.L.D. “RMA-FL patients will now have access to technologies pioneered at RMANJ, such as comprehensive chromosome screening, which more accurately detects healthy embryos that will lead to successful pregnancies and healthy deliveries.”
Patients can make appointments by calling 407-804-9670.
IVI-RMA Global was founded in 2017 when the Valencian Infertility Institute (IVI) merged with Reproductive Medicine Associates of New Jersey (RMANJ). Together, the companies comprise the largest group dedicated to assisted reproduction in the world. IVI-RMA Global currently has more than 70 centers in 12 countries with practices in the United States, Spain, Portugal, Italy, United Kingdom, Mexico, Panama, Argentina, Chile, Brazil, UAE and India. For more information visit: IVI-Fertility.com. RMANJ is the organization’s US flagship practice and currently has 25 physicians and 10 locations in New Jersey: Basking Ridge, Eatontown, Englewood, Freehold, Hamilton, Morristown, Somerset, Springfield, West Orange, and its newest location in Marlton, New Jersey. For more information visit RMANJ.com.
Melissa Drake, Director of Marketing and Communication
RMANJ, an IVI-RMA Global Company
(973) 871-1266 (direct)
Gloria Quinn Doyle
Group Vice President, Kaplow Communications
*SART 2014 Final Live Birth Per Egg Retrieval Cycle of 72.4% under 35 years. This is your chance of achieving a live birth for each cycle started for an egg retrieval. This includes all transfers performed with fresh and frozen embryos derived from this cycle. Please note a comparison of clinic success rates may not be meaningful because a patient’s medical characteristics, treatment approaches and entrance criteria for assisted reproductive technology (ART) may vary from clinic to clinic. Visit www.sart.org to learn more.